Academic literature on the topic 'Cerebral lymphoma'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cerebral lymphoma.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cerebral lymphoma"

1

Brown, J. H., M. J. Stallmeyer, E. S. Lustrin, and F. S. Chew. "Primary cerebral lymphoma." American Journal of Roentgenology 165, no. 3 (September 1995): 626. http://dx.doi.org/10.2214/ajr.165.3.7645482.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hughes-Davies, L., M. Spittle, M. J. Harrison, S. B. Lucas, and R. F. Miller. "Metastatic cerebral lymphoma." Sexually Transmitted Infections 67, no. 4 (August 1, 1991): 284–90. http://dx.doi.org/10.1136/sti.67.4.284.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lanfermann, H., W. Heindel, J. Schaper, R. Schröder, M. L. Hansmann, R. Lehrke, R. I. Ernestus, and K. Lackner. "CT and MR imaging in primary cerebral Non-Hodgkin's lymphoma." Acta Radiologica 38, no. 2 (March 1997): 259–67. http://dx.doi.org/10.1080/02841859709172060.

Full text
Abstract:
Purpose: to determine the morphological appearance and topographical distribution of primary cerebral non-Hodgkin's lymphoma (NHL). Material and Methods: CT and MR examinations of 68 patients with primary cerebral NHL were analyzed. the NHLs were classified by the Kiel classification and im-munohistological data, as centroblastic (25), immunoblastic (24), lymphoblastic (5), Burkitt (1), non-subclassifiable type B (11), and T-cell lymphoma (2). Results: Centroblastic lymphomas tended to predominate in the parietal lobe (56.5%) and the corpus callosum (59.1%) while immunoblastic lymphomas were mainly distributed in the frontal lobe (52.8%). About 2/3 of all NHLs showed a multi-focal occurrence. Important for differential diagnosis, ventricular involvement was proved in 83.3% of these cases. in the remaining 26 patients with a solitary lymphoma, a periventricular location could be detected in only 8 cases. Central necroses were frequent in HIV-positive patients (7/11, 63.6%) but rare in the HIV-negative patients (9/57,15.8%). on T2-weighted SE MR images, 8/11 centroblastic lymphomas gave a signal that was isointense with, or lower than, that of the contralateral white matter, while 8/10 immunoblastic lymphomas gave a higher signal. Conclusion: the radiological finding of multifocal brain lesions with ventricular involvement is relatively specific for primary cerebral NHL. However, subclassification on the basis of the CT or MR imaging results is not yet possible.
APA, Harvard, Vancouver, ISO, and other styles
4

PAPPERT, ERIC J., JOSEPH C. PARKER, and ANN HUBBARD. "Cerebral Lymphoma in Childhood." Southern Medical Journal 82, no. 10 (October 1989): 1294–98. http://dx.doi.org/10.1097/00007611-198910000-00026.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Faia, Lisa J., and Chi-Chao Chan. "Primary Intraocular Lymphoma." Archives of Pathology & Laboratory Medicine 133, no. 8 (August 1, 2009): 1228–32. http://dx.doi.org/10.5858/133.8.1228.

Full text
Abstract:
Abstract Primary intraocular lymphoma, recently suggested to be renamed primary retinal lymphoma, is a subset of primary central nervous system lymphoma and is usually an aggressive diffuse large B-cell lymphoma. Between 56% and 85% of patients who initially present with primary intraocular lymphoma alone will develop cerebral lesions. Patients typically complain of decreased vision and floaters, most likely secondary to the chronic vitritis and subretinal lesions. The diagnosis of primary intraocular lymphoma can be difficult to make and requires tissue for diagnosis. The atypical lymphoid cells are large and display a high nuclear to cytoplasmic ratio, prominent nucleoli, and basophilic cytoplasm. Flow cytometry, immunohistochemistry, cytokine analysis, and gene rearrangements also aid in the diagnosis. Local and systemic treatments, such as chemotherapy and radiation, are employed, although the relapse rate remains high.
APA, Harvard, Vancouver, ISO, and other styles
6

Lutz, J.-M., and MP Coleman. "Trends in primary cerebral lymphoma." British Journal of Cancer 70, no. 4 (October 1994): 716–18. http://dx.doi.org/10.1038/bjc.1994.381.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Plum, F. "Cerebral Lymphoma and Central Hyperventilation." Archives of Neurology 47, no. 1 (January 1, 1990): 10. http://dx.doi.org/10.1001/archneur.1990.00530010016001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kaur, A., A. Clarke-Brodber, M. Eldibany, M. Alikhan, and J. Lee. "Lymphamatosis Cerebri With Rare Marginal Zone Lymphoma Phenotype: An Autopsy Case Report In A Patient With History Of Peripheral Diffuse Large B Cell Lymphoma And Chronic Lymphocytic Leukemia." American Journal of Clinical Pathology 154, Supplement_1 (October 2020): S82—S83. http://dx.doi.org/10.1093/ajcp/aqaa161.181.

Full text
Abstract:
Abstract Introduction/Objective Lymphomatosis cerebri (LC) is a term used to describe primary central nervous system lymphomas which may present as diffuse, non-enhancing, infiltrative lesions. Although most of these are diffuse large B-cell lymphomas, there are other cases in the literature of low-grade B-cell lymphoma, Burkitt lymphoma and T-cell lymphoma. Methods We present a 76-year-old male with a past medical history of chronic lymphocytic leukemia (2014), diffuse large B cell lymphoma of right jaw (2019) s/p chemotherapy, prostate cancer s/p prostatectomy and radiation. The patient presented 3 weeks prior to admission due to generalized weakness with rapidly declining mental status, anorexia and deconditioning. MRI brain revealed scattered T2/FLAIR signal abnormalities in the cerebrum and cerebellum. An assessment of encephalitis was rendered. The patient continued to worsen and passed away. Results On autopsy of the brain, there was extensive involvement of the basal ganglia, cerebellum and all cerebral lobes by a lymphoid process. It had a predominant perivascular, parenchymal and leptomeningeal distribution. Microscopically, there was a diffuse proliferation of small to intermediate sized lymphocytes with mature chromatin. These lymphocytes were neoplastic B cells which stained for CD20, CD43 and negative for CD5, CD3 and CD23. It also showed low Ki67 index. This immunophenotype is most consistent with a marginal zone lymphoma. Conclusion It is quite rare that our patient’s infiltrative process was a small mature B-cell lymphoma most compatible with marginal zone B-cell lymphoma. Our case illustrates the importance of recognizing this entity, particularly in context with different morphology since our patient had three different types of lymphoma. The dilemma in diagnosing such lesions can lead to delay in diagnosis and institution of appropriate management. Thus, knowledge about its imaging and morphological features is very critical for correct categorization and to avoid potential misdiagnosis.
APA, Harvard, Vancouver, ISO, and other styles
9

Degl’Innocenti, Sara, Nicola Della Camera, Cristian Falzone, and Carlo Cantile. "Canine Cerebral Intravascular Lymphoma: Neuropathological and Immunohistochemical Findings." Veterinary Pathology 56, no. 2 (October 5, 2018): 239–43. http://dx.doi.org/10.1177/0300985818806059.

Full text
Abstract:
Intravascular lymphoma (IVL) is a rare angiotropic large-cell lymphoma in which neoplastic lymphocytes proliferate within the lumina of small blood vessels in the absence of a primary extravascular mass or leukemia. This study included 10 cases of canine IVL restricted to the CNS. Dogs had an average age of 8 years and neurological signs mainly referred to brain involvement such as depression, seizures, and ambulatory deficits. Gross examination at necropsy showed focal extensive or multiple hemorrhagic areas mainly distributed in the telencephalon and diencephalon. Histopathologically, numerous veins and capillaries were filled with neoplastic lymphoid cells, accompanied by edema, hemorrhage, and thrombosis. Immunohistochemistry (IHC) for CD3, CD20, and PAX5 was performed to phenotype the neoplastic lymphocytes. IHC for CD44 and CD29 were used to investigate the pathogenetic mechanism leading to the intravascular aggregation of the neoplastic lymphocytes. The same IHC panel was applied to 8 cases of primary and metastatic canine CNS lymphoma in order to compare IVL immunoreactivity. Three IVLs were typified as T-cell, 3 as B-cell, and 4 as non-T non-B. Neoplastic lymphocytes showed marked expression of CD44 in all IVL cases, and CD29-immunolabeled cells were observed in 4 IVLs. CD44 immunoreactivity was consistent with the findings reported in human IVL, suggesting a predisposition to the formation of lymphocyte aggregates. CD29 was inconsistently immunonegative in canine IVL, confirming only partially the pathogenetic mechanism suggested for the human counterpart.
APA, Harvard, Vancouver, ISO, and other styles
10

Maas, Jared A., Manuel Menes, and Vitaly Siomin. "Cardiac Myxoma with Cerebral Metastases and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Case Report and Review." Journal of Neurological Surgery Reports 81, no. 01 (January 2020): e1-e6. http://dx.doi.org/10.1055/s-0039-3399570.

Full text
Abstract:
Abstract Background Cardiac myxomas, the most common primary cardiac tumors, are generally benign neoplasms. Primary cardiac lymphoma is a rare cardiac malignancy with a very poor prognosis. Here we present a case of a cardiac myxoma with cerebral metastases and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) arising within the cerebral metastases. Case description A 62-year-old man, who presented with symptoms of multiple transient ischemic attacks, was found to have a left atrial myxoma. Twelve months after excision of the myxoma, the patient experienced a recurrence of neurologic symptoms. Brain magnetic resonance imaging revealed multiple hemorrhagic masses. Craniotomy was performed to resect the lesions. Histopathologic examination confirmed cardiac myxoma metastases and a small lymphocytic infiltrate within the tumor consistent with CLL/SLL. Conclusion Including the present case, there are 27 cases of cardiac myxoma cerebral metastases and 22 cases of lymphomas arising within myxomas. The present case is the first known instance of both entities in the same patient. There is no standard management for either cardiac myxoma metastases or lymphoma within a myxoma. For both diseases, surgical excision is the primary treatment modality, but postoperative chemotherapy and/or radiation have been attempted. Myxomas may create a chronic inflammatory state that could lead to the development of CLL/SLL.
APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Cerebral lymphoma"

1

SHIBUI, SOICHIRO, YASUJI MIYAKITA, YOSHITAKA NARITA, and HIROYUKI MOMOTA. "INTRAVASCULAR LYMPHOMA OF THE CENTRAL NERVOUS SYSTEM PRESENTING AS MULTIPLE CEREBRAL INFARCTIONS." Nagoya University School of Medicine, 2012. http://hdl.handle.net/2237/16746.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rozenblum, Laura. "Nouveaux biomarqueurs d'imagerie pour la prise en charge des lymphomes primitifs du système nerveux central : études en TEP-IRM au 18F-FDG et à la 18F-FLUDARABINE." Electronic Thesis or Diss., Sorbonne université, 2024. https://accesdistant.sorbonne-universite.fr/login?url=https://theses-intra.sorbonne-universite.fr/2024SORUS150.pdf.

Full text
Abstract:
Le lymphome primitif du système nerveux central (LPSNC) est une pathologie au pronostic sombre, dont l'incidence est en hausse, notamment chez les patients âgés et immunocompétents. La démarche thérapeutique pour les patients atteints de LPSNC s'appuie sur l'évaluation de deux indicateurs pronostiques établis : l'âge et le performans status. Néanmoins, la nécessité d'améliorer les stratégies thérapeutiques actuelles, centrées sur une poly-chimiothérapie d'induction à base de méthotrexate à haute dose suivie potentiellement par un traitement d'entretien, a suscité un intérêt croissant dans l'identification de nouveaux biomarqueurs. Cette thèse se positionne dans ce contexte de recherche et d'innovation dans les LPSNC, promue par le réseau LOC (lymphome oculo-cérébral) en France, et visant à améliorer la stratification pronostique et le suivi thérapeutique chez ces patients.L'imagerie par résonance magnétique (IRM) cérébrale constitue aujourd'hui le gold standard dans le suivi des LPSNC. Cependant, plusieurs études récentes ont mis en évidence ses limites, en particulier devant le pourcentage élevé de patients récidivants rapidement malgré une réponse jugée complète sur l'évaluation de fin de traitement. Notre recherche explore le potentiel de la tomographie par émission de positon (TEP) au 18F-Fluorodeoxyglucose (FDG) combinée à l'IRM comme outil innovant dans la prise en charge des patients atteints de LPSNC. Cette recherche s'est articulée autour de trois axes principaux: d'une part la recherche de biomarqueurs TEP-IRM pronostiques de la réponse de fin de traitement d'induction, d'autre part l'évaluation de cette technique comme outil d'évaluation précoce de la réponse sous chimiothérapie et enfin l'exploitation de méthode d'intelligence artificielle pour affiner la compréhension physiopathologique via des analyses radiomiques poussées, et élaborer un modèle prédictif en deep-learning, généralisable à large échelle. Ce travail s'appuie sur les données prospectives longitudinales de la cohorte Localyse, une étude ancillaire de l'essai multicentrique de phase III BLOCAGE-01, qui étudie l'intérêt d'une chimiothérapie de maintenance chez les patients âgés, immunocompétents, atteints de LPSNC. Les résultats de ce travail doctoral ont permis l'identification de deux nouveaux biomarqueurs pronostiques en TEP FDG dans les LPSNC et ont démontré la supériorité potentielle de la TEP interim pour évaluer la réponse thérapeutique après deux cycles de chimiothérapie en comparaison avec l'IRM interim. Intégrant les avancées les plus récentes en matière d'analyse radiomique et d'apprentissage profond, cette thèse s'inscrit dans le développement d'outil robuste et novateur en IA appliquée à la neuro-oncologie. Enfin, elle examine le potentiel de la 18F-Fludarabine, un radiotraceur ciblant spécifiquement les lymphocytes B, qui pourrait offrir de nouvelles perspectives dans la prise en charge des patients atteints de LPSNC dans le futur. En conclusion, nos travaux contribuent au développement de nouveaux outils facilitant la gestion des patients atteints de LPSNC et ouvrent la voie au développement de stratégies thérapeutiques guidées par la TEP
Primary central nervous system lymphoma (PCNSL) is a malignancy with a dismal prognosis, increasingly prevalent, especially among elderly and immunocompetent patients. The therapeutic approach for PCNSL relies on evaluating established prognostic indicators: patient age and performance status. However, there is a growing need to enhance current therapeutic strategies, which are centered on high-dose methotrexate-based induction polychemotherapy, potentially followed by maintenance treatment. This has encouraged interest in identifying new biomarkers. This thesis positions itself within this research and innovation framework in PCNSL, supported by the LOC network (Lymphome Oculo-Cerebraux) in France, aiming to improve prognostic stratification and therapeutic monitoring for these patients. Currently, cerebral magnetic resonance imaging (MRI) is the gold standard for PCNSL follow-up. However, recent studies have highlighted its limitations, notably the high percentage of patients relapsing rapidly despite a complete response on end-of-treatment evaluation. Our research investigates the potential of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) combined with MRI as an innovative tool in the management of PCNSL patients. The study is structured around three main axes: firstly, exploring PET-MRI FDG as a prognostic biomarker for end-of-induction treatment response; secondly, its utility as a tool for early evaluation of the chemotherapy response; and finally, exploiting artificial intelligence methods to refine the pathophysiological understanding through advanced radiomic analyses, and to develop a predictive deep-learning model scalable for broad application. This work relied on the the longitudinal prospective data from the Localyse cohort, an ancillary study of the phase III multicentric BLOCAGE-01 trial, investigating the utility of maintenance chemotherapy in aged, immunocompetent patients. The results of this doctoral research identified two novel prognostic biomarkers in FDG-PET for PCNSL and demonstrated the potential superiority of interim PET over interim MRI in assessing the therapeutic response post two chemotherapy cycles. Incorporating the latest advances in radiomic analysis and deep learning, this thesis contributes to the development of robust and innovative tools in AI applied to neuro-oncology. Lastly, it examines the potential of 18F-Fludarabine, a radiotracer specifically targeting B lymphocytes, which could offer new perspectives in the future management of PCNSL patients. In conclusion, our work facilitates the development of new tools for managing PCNSL patients, paving the way for treatment strategies guided by PET findings
APA, Harvard, Vancouver, ISO, and other styles
3

Cohen-Hadria, Cailleres Sylvie. "Lymphomes cerebraux primitifs : a propos de 12 cas." Aix-Marseille 2, 1990. http://www.theses.fr/1990AIX20906.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

LECLERE, SYLVIE. "Epilepsie myoclonique progressive et localisations cerebrales d'un lymphome : etude d'un cas." Clermont-Ferrand 1, 1993. http://www.theses.fr/1993CLF1M013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

LEMERCIER, BERTOUT CATHERINE. "Lymphomes cerebraux primitifs : revue de la litterature a propos de 19 observations." Nantes, 1990. http://www.theses.fr/1990NANT104M.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

CANAPLE, BONNAY SANDRINE. "Lymphomes cerebraux primitifs : aspects cliniques, neuroradiologiques, therapeutiques et pronostiques ; resultats du protocole lcp 88 ; a propos de 48 patients." Amiens, 1993. http://www.theses.fr/1993AMIEM026.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

BELAIDI, MOURAD. "Aspects radiologiques des lymphomes malins non hodgkiniens primitifs cerebraux : a propos de 9 cas." Nice, 1993. http://www.theses.fr/1993NICE6521.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

CAMILLERI-BROET, SOPHIE. "Apoptose et lymphomes cerebraux primitifs : interaction entre le virus ebv et les proteines de la famille bcl-2." Paris 6, 2000. http://www.theses.fr/2000PA066494.

Full text
Abstract:
Les lymphomes cerebraux primitifs (lcp) du sida sont caracterises a l'inverse de ceux des patients immunocompetents par une association quasi-constante au virus d'epstein barr (ebv), un type histologique souvent immunoblastique avec une differenciation plasmocytaire, une necrose extensive, une forte expression des marqueurs d'activation lymphocytaire b, d'adherence cellulaire et une augmentation de l'expression de molecules de la famille bcl-2 (bcl-2, bcl-x et bax). Le phenotype des lcp du sida differe de celui des lymphomes systematiques du sida, ce qui suggere un role particulier de la localisation cerebrale, caracterisee par son statut immunitaire privilegie. En revanche, il est identique au phenotype des lignees cellulaires infectees par l'ebv in vitro (lignees lymphoblastoides, cellules de burkitt), ce qui suggere un role predominant du virus ebv. Il est probable que le systeme nerveux central permette une meilleure expression des proteines de latence virale (lmp1, ebna2) en reconstituant in vivo les conditions qui existent in vitro. Malgre une augmentation de l'expression des proteines bcl-2, bcl-x et bax, nous n'avons pas mis en evidence de difference significative du taux d'apoptose dans les lcp des patients atteints de sida par rapport aux lcp des patients immunocompetents. Dans une autre etude, nous avons montre que dans certains modeles d'apoptose, la proteine bcl-2 etait inefficace pour bloquer l'apoptose. En effet, dans un grand nombre de modeles, la proteine bcl-2 inhibe l'apoptose en bloquant les modifications mitochondriales (chute du potentiel transmembranaire), etape precoce du processus. Dans d'autres modeles, (par exemple les cellules cho traitees par l'aphidicoline) il existe une proliferation de mitochondries
APA, Harvard, Vancouver, ISO, and other styles
9

Schiergens, Isabell. "Prognostischer Wert des magnetresonanztomographisch bestimmten Tumoransprechens und des kumulativen Methotrexat-Serumspiegels bei immunkompetenten Patienten mit primär cerebralen Lymphomen nach kombinierter systemischer und intraventrikulärer Chemotherapie /." Bonn, 2009. http://opac.nebis.ch/cgi-bin/showAbstract.pl?sys=000263392.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Gómez-Choco, Cuesta Manuel Jesús. "Identificación de la presencia de antígenos neurales en el tejido linfoide de los pacientes con ictus y análisis de su eventual implicación patogénica en la respuesta inmune adaptativa tras el daño cerebral." Doctoral thesis, Universitat de Barcelona, 2014. http://hdl.handle.net/10803/285579.

Full text
Abstract:
INTRODUCCION: En condiciones fisiológicas existe un drenaje de solutos y células del sistema inmune desde el sistema nervioso central hacia el tejido linfoide secundario, pudiendo desarrollarse una respuesta inmune de tipo adaptativo frente a dichos antígenos. Ciertas moléculas coadyuvantes como heat shock protein 70(Hsp-70) pueden facilitar y modular los procesos de presentación antigénica y la propia respuesta inmune. Hsp-70 es producida en gran cantidad durante la isquemia cerebral. En los pacientes con ictus isquémico podría haber una mayor llegada de antígenos cerebrales y moléculas coadyuvantes al tejido linfoide secundario que en sujetos controles y de este modo favorecerse respuestas inmunes que influyan en la evolución y pronóstico del ictus. MÉTODOS: Estudio de tejido linfoide en pacientes con ictus agudo mediante toma de biopsias de amígdala palatina y análisis de muestras de sangre, así como en sujetos control. Así mismo, toma de muestras de amígdala palatina y ganglio linfático cervical en necropsias de pacientes con ictus y necropsias control. Se estudiaron las diferentes subpoblaciones linfocitarias, marcadores de activación linfocitaria, presencia de antígenos cerebrales y la proteína Hsp-70, y estructura del tejido linfoide mediante técnicas de citometría de flujo, inmunofluorescencia y western blot, realizándose un análisis cuantitativo. Se analizó la síntesis local tanto de antígenos como Hsp-70 mediante técnica de PCR. RESULTADOS: No se observaron diferencias ni en la estructura del tejido linfoide ni en las diferentes subpoblaciones linfocitarias entre pacientes y controles. Los antígenos cerebrales y Hsp-70 se encontraron en mayor cantidad en pacientes con ictus. Ambos estaban localizados en células presentadoras de antígenos con capacidad para activar el sistema inmune. Dichas células portadoras de antígenos cerebrales se encuentran preferentemente localizadas próximas a la trama fibroreticular del tejido linfoide y podían llevar a cabo algún grado de activación linfocitaria. Los pacientes que presentaban mas antígenos neurales presentaban mejor pronostico, mientras que aquellos con mayor presencia de antígenos mielínicos tenían un mayor volumen de infarto y peor pronóstico. CONCLUSIONES: En los pacientes con ictus isquémico se observa un incremento de antígenos cerebrales en el tejido linfoide secundario. La respuesta inmune frente a ellos puede influir en la evolución y pronóstico de la enfermedad.
INTRODUCTION: Under physiological conditions solutes and immune system cells drain from the central nervous system to the secondary lymphoid tissue. An immune response against these antigens can be developed. Certain adjuvant molecules as heat shock protein 70 (HSP -70) can facilitate and modulate the process of antigen presentation and the immune responses. Hsp -70 is produced in large quantities during cerebral ischemia . In patients with ischemic stroke there could be a increased arrival of brain antigens and adjuvant molecules to the secondary lymphoid tissue and this could favor the development of immune responses that could have a role in the evolution and prognosis of stroke. METHODS: We performed a biopsy of palatine tonsil to acute stroke patients and control subjects. We also obtained samples of palatine tonsil and cervical lymph node from necropsies of patients with stroke and controls. Different lymphocyte subsets, lymphocyte activation markers, presence of brain antigens and Hsp -70 protein, and lymphoid tissue structure were studied by flow cytometry, immunofluorescence and western blot techniques. RESULTS: No differences were observed in either the structure of lymphoid tissue or in different lymphocyte subpopulations between patients and controls. Brain antigens and Hsp -70 were increased in the lymphoid tissue of patients with stroke. Both were located on antigen-presenting cells with ability to activate the immune system. These antigen-presenting cells carrying brain antigens were preferably located near the fibroreticular mesh of the lymphoid tissue and performed some degree of lymphocyte activation. Patients who had more neural antigens showed better prognosis, whereas those with greater presence of myelinated antigens had an increased infarct volume and worse prognosis. CONCLUSIONS: We observed that brain antigens were increased in the secondary lymphoid tissue of stroke patients . The development of an immune response against them could influence the evolution and prognosis of the disease.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Cerebral lymphoma"

1

Carton, James. Neuropathology. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198759584.003.0018.

Full text
Abstract:
This chapter discusses neuropathology, including nervous system malformations, epilepsy, head injury, cerebral infarction, intracerebral haemorrhage, subarachnoid haemorrhage, meningitis, cerebral infections, multiple sclerosis, Guillain–Barré syndrome, myasthenia gravis, Alzheimer’s disease, vascular dementia, dementia with Lewy bodies, Parkinson’s disease, Huntington’s disease, motor neurone disease, Creutzfeldt–Jacob disease, astrocytomas (including glioblastoma), oligodendroglioma, ependymoma, meningioma, medulloblastoma, primary CNS lymphomas, and cerebral metastases.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Cerebral lymphoma"

1

Moss, T. H. "Primary Cerebral Lymphoma." In Tumours of the Nervous System, 145–49. London: Springer London, 1986. http://dx.doi.org/10.1007/978-1-4471-1426-0_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gumerlock, Mary Kay, and Edward A. Neuwelt. "Primary cerebral lymphoma." In Cancer Treatment and Research, 111–26. Boston, MA: Springer US, 1993. http://dx.doi.org/10.1007/978-1-4615-3084-8_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Amin-Hanjani, Sepideh, and Griffith R. Harsh. "Tumors: Cerebral Metastases and Lymphoma." In Neurosurgery, 281–97. London: Springer London, 2005. http://dx.doi.org/10.1007/1-84628-051-6_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Amin-Hanjani, Sepideh, and Griffith R. Harsh. "Tumors: Cerebral Metastases and Lymphoma." In Tumor Neurosurgery, 281–97. London: Springer London, 2006. http://dx.doi.org/10.1007/978-1-84628-294-2_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Gerhard, L., H. C. Nahser, and V. Reinhardt. "Clinical Differential Diagnosis of Cerebral Manifestations of Lymphoma." In Extra-Intracranial Vascular Anastomoses Microsurgery at the Edge of the Tentorium, 282–84. Berlin, Heidelberg: Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-642-70603-5_43.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

"26 Natural History and Management Options of Cerebral Lymphoma cerebral lymphomas." In Neurosurgical Diseases, edited by Leon T. Lai and Cristian Gragnaniello. New York, NY: Thieme Medical Publishers, Inc., 2022. http://dx.doi.org/10.1055/b-0041-184157.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Abarbanel, David N., and Ivan D. Carabenciov. "Night Sweats and Paraparesis." In Mayo Clinic Cases in Neuroimmunology, edited by Andrew McKeon, B. Mark Keegan, and W. Oliver Tobin, 199–201. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780197583425.003.0064.

Full text
Abstract:
A 78-year-old man sought care for saddle anesthesia, left lower extremity numbness, and bilateral lower extremity weakness. The sensory loss occurred suddenly, starting initially in the left perianal region and over the course of 3 hours extending down to involve the entirety of the left lower extremity. Symptoms were stable until 3 weeks later, when he had a few episodes of urinary incontinence. Diffuse, severe, bilateral, lower extremity weakness developed. The patient reported 6 months of intermittent night sweats. Serum studies were notable for pancytopenia and increased erythrocyte sedimentation rate and levels of ferritin and lactate dehydrogenase. Lumbar puncture showed a mildly increased protein concentration with normal blood cell count, glucose value, and cytologic and flow cytometry findings. Magnetic resonance imaging showed multifocal regions of increased T2 signal throughout the central nervous system including the cerebrum, cerebellum, upper cervical cord, lower thoracic cord, and conus medullaris. Gadolinium enhancement was present in the corpus callosum, cerebellum, and dorsal lower thoracic cord. One week later, 18F-fludeoxyglucose–positron emission tomography/computed tomography showed patchy 18F-fludeoxyglucose activity in the cerebral parenchyma, as well as 2 cutaneous, 18F-fludeoxyglucose-avid soft-tissue nodules. Fine-needle aspiration of 1 of these nodules indicated diffuse large B-cell lymphoma, with no dysplastic abnormalities identified on subsequent bone marrow biopsy. Incisional biopsy of the second soft-tissue nodule showed foci of diffuse large B-cell lymphoma adherent to the lumina of a few small arteries, consistent with a diagnosis of intravascular lymphoma. The patient was diagnosed with intravascular large B-cell lymphoma. At initial evaluation at an outside facility, empiric intravenous corticosteroids were administered. After the biopsy findings of intravascular large B-cell lymphoma, he was started on intermediate-dose methotrexate followed by rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy. He continued to experience severe, bilateral, lower extremity weakness and sensory loss. Two months after diagnosis of intravascular large B-cell lymphoma, he died of medical complications from chemotherapy. Intravascular lymphoma is a rare lymphoma subtype that is typically of B-cell origin. The neoplastic cells preferentially grow within the lumen of blood vessels, potentially due to a lack of cellular machinery required for cellular extravasation and parenchymal invasion.
APA, Harvard, Vancouver, ISO, and other styles
8

Brew, Bruce James. "Uncommon Causes Of Predominantly Focal Cerebral Complications In Advanced HIV Disease." In HIV Neurology, 152–61. Oxford University PressNew York, NY, 2001. http://dx.doi.org/10.1093/oso/9780195133639.003.0016.

Full text
Abstract:
Abstract Although it is true that the most common causes of focal brain disease in patients with acquired immunodeficiency syndrome (AIDS) are toxoplasmosis, primary central nervous system lymphoma, and progressive multifocal leukoencephalopathy, there are several other less common yet important entities. Most have pleomorphic presentations leading to both focal and nonfocal disease. Indeed, all the complications discussed in this chapter more often cause diffuse, nonfocal disorders except herpes simplex, Kaposi’s sarcoma, cerebral hemorrhage, and primary brain tumors. In these cases, the focal presentations are discussed in detail here and the nonfocal aspects are discussed in other chapters. All of these disorders are important because diagnosis has become easier with the development of a variety of molecular techniques and because many respond to therapy.
APA, Harvard, Vancouver, ISO, and other styles
9

Brew, Bruce James. "Importance Of HIV Neurologic Complications To The Neurologist And Physician." In HIV Neurology, 3–7. Oxford University PressNew York, NY, 2001. http://dx.doi.org/10.1093/oso/9780195133639.003.0001.

Full text
Abstract:
Abstract Neurologic complications of human immunodeficiency virus (HIV) disease are important to both neurologists and physicians for a variety of reasons. Perhaps the most significant is that neurologic complications are common. At least one-third of patients with advanced HIV disease will present with a neurologic complication, and even greater numbers of patients will have experienced one or more neurologic complication during their life with HIV disease. At autopsy, more than 80% of patients will have cerebral pathology, ranging from evidence of HIV encephalitis to opportunistic infections and lymphoma. At least half will have some evidence of a peripheral neuropathy.–These figures are evident in those countries where there is limited or no access to antiretroviral drugs as well as in those countries with full access to such drugs.
APA, Harvard, Vancouver, ISO, and other styles
10

Meissner, Dr Irene. "Diffuse B-cell lymphoma (primary central nervous system lymphoma[PCNSL])." In Fifty Neurologic Cases From Mayo Clinic, 149–52. Oxford University PressNew York, NY, 2004. http://dx.doi.org/10.1093/oso/9780195177442.003.0037.

Full text
Abstract:
Abstract The patient presented with a subacute progressive process that occurred over several months and affected cognition, multiple cranial nerves, and sympathetic, cerebellar, and pyramidal tracts, with associated imaging abnormalities. The symptoms of subtle cognitive changes, hearing loss (superimposed on known occupational hearing deficits), and multifocal white matter changes can be seen in many disorders. These include demyelinating processes, inflammatory disorders such as the microangiopathy of Susac’s syndrome (retinocochleocerebral vestibulopathy), sarcoidosis, Behçet’s syndrome, Listeria rhombencephalitis, and infiltrative tumors such as lymphoma or gliomatosis cerebri. In our patient, a brain biopsy specimen contained tumor cells positive for CD20 and CD79a, with a light chain restriction supporting the diagnosis of diffuse B-cell lymphoma (PCNSL).
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cerebral lymphoma"

1

Decalmer, Samantha, Rebecca Heath, Pippa Newton, Mark Roberts, and Robert M. Niven. "Epstein Barr Infection And Primary Cerebral Lymphoma In An Immune-Suppressed Patient With Churg-Strauss Syndrome And Severe Asthma." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6596.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yamasaki, Toshihiko, Tsuhan Chen, Toshinori Hirai, and Ryuji Murakami. "Differentiating cerebral lymphomas and GBMs featuring luminance distribution analysis." In SPIE Medical Imaging, edited by Carol L. Novak and Stephen Aylward. SPIE, 2013. http://dx.doi.org/10.1117/12.2006110.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Cerebral lymphoma"

1

Deeren, Dries. Cure of cerebral lymphoma with only one course of chemotherapy: was dr. House right after all? Science Repository, July 2019. http://dx.doi.org/10.31487/j.rgm.2019.02.01.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography